Collegium Pharmaceutical (COLL) Capital Expenditures Growth (1y) (2016 - 2026)
Collegium Pharmaceutical (COLL) Capital Expenditures Growth (1y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | 8.33% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | -19.86% |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | -1.95% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 73.63% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -0.19% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | -37.60% |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | -42.11% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Collegium Pharmaceutical | 902.41 Mn | 753.09 Mn | 110.29 Mn | 663.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 663.08% |
| Mar 31, 2026 | -74.06% |
| Dec 31, 2025 | 18.39% |
| Sep 30, 2025 | -78.68% |
| Jun 30, 2025 | 117.66% |
| Mar 31, 2025 | 40.49% |
| Dec 31, 2024 | -646.95% |
| Sep 30, 2024 | 1,256.92% |
| Jun 30, 2024 | -757.14% |
| Mar 31, 2024 | 222.73% |
| Dec 31, 2023 | -82.55% |
| Sep 30, 2023 | -42.48% |
| Jun 30, 2023 | -87.85% |
| Mar 31, 2023 | 62.96% |
| Dec 31, 2022 | 82.52% |
| Sep 30, 2022 | -59.06% |
| Jun 30, 2022 | -36.41% |
| Mar 31, 2022 | -74.77% |
| Dec 31, 2021 | -65.23% |
| Sep 30, 2021 | -88.51% |